-- Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,240.72, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $882.98, Change: $-36.93, Percent Change: -4.01%
Top cryptocurrencies fell Tuesday, with Bitcoin (BTC-USD) dropping below the $75,000 level.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, fell almost 0.6% in the past 24 hours. The Nasdaq 100 fell 0.5%, the S&P 500 and the Dow Jones Industrial Average were down about 0.6% each.Bitcoin dropped 1.7% to $74,985, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume fell 7.1% to $37.1 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, dipped 1.4% to $2,297.XRP (XRP-USD) declined 1%, BNB (BNB-USD) fell 0.7%, and Solana (SOL-USD) shed 1.6%. Dogecoin (DOGE-USD) dropped 1.6%, and Cardano (ADA-USD) lost 1.6%.The US 10-year Treasury yield stood at 4.289% at 3 p.m. ET Tuesday, up from 4.248% Monday, while the five-year yield rose to 3.906% from 3.848%.The total market value of the cryptocurrency industry fell 0.6% in the past 24 hours to $2.55 trillion, with trading volume declining 1.5% to $153.37 billion.Price: $74991.13, Change: $-863.67, Percent Change: -1.14%
Financial stocks were declining in late Tuesday afternoon trading, with the NYSE Financial Index decreasing 0.6% and the State Street Financial Select Sector SPDR ETF (XLF) off by 0.3%.The Philadelphia Housing Index was adding 0.8%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) fell 1.6%.Bitcoin (BTC-USD) was decreasing 0.2% to $75,717, and the yield for 10-year US Treasuries rose 4.2 basis points to 4.29%.In economic news, US retail sales rose 1.7% in March, above the 1.4% increase expected in a Bloomberg-compiled survey and following the previous month's revised 0.7% gain. Removing both motor vehicles and a 15.5% surge in gasoline station sales, retail sales were up 0.6% in March, the same as in February.US pending home sales increased more than expected in March despite higher mortgage rates, data from the National Association of Realtors showed.In corporate news, JPMorgan Chase (JPM) is working to secure approval from securities regulators in China to launch actively managed exchange-traded funds in the country for the first time, Bloomberg reported. JPMorgan shares were down 1.3%.Coinbase (COIN) and Gemini Titan have been sued by New York Attorney General Letitia James for allegedly violating the state laws against illegal gambling with their prediction markets, Reuters reported, citing complaints filed in a state court in Manhattan. Coinbase shares fell past 7%.Washington Trust Bancorp (WASH) reported late Monday a year-over-year decline in Q1 revenue that also trailed analysts' estimates. Its shares tumbled nearly 17%.Barclays (BCS) is facing scrutiny from UK regulators over its use of significant risk transfer, or SRT, transactions, Bloomberg reported. The review, known as a Section 166 probe, has been requested by the Prudential Regulation Authority, the supervisory arm of the Bank of England, the report said. Barclays shares fell 2.9%.
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 1%.In corporate news, Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a randomized study to support approval of its experimental treatment PBFT02, a move that adds time, cost, and uncertainty, Wedbush said Tuesday in a report. Wedbush downgraded Passage Bio's stock to neutral from outperform and cut its price target to $8 from $32. Passage Bio shares dropped 2.9%.Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.7%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 7%.Quest Diagnostics (DGX) shares popped more than 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.